Group 1 - The Shanghai Composite Index rose by 0.96%, closing at 3617.6 points, while the Hang Seng Index increased by 0.68%, closing at 24902.53 points [1] - The premium of Haiprui's A-shares over H-shares reached 125.21%, ranking 16th among AH shares [1] - Haiprui's A-shares closed at 13.26 yuan, with a gain of 0.68%, and H-shares closed at 6.43 HKD, up by 3.38% [1] Group 2 - Shenzhen Haiprui Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [1] - The company's main business covers the entire heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [1] - Haiprui's three business segments are synergistic, driven by unmet clinical needs, aiming to provide high-quality, safe, and effective drugs and services to global patients [1]

Group 1 - The Shanghai Composite Index rose by 0.66% to close at 3583.31 points, while the Hang Seng Index increased by 0.92% to 24733.45 points [1] - The premium of Haiprui's A-shares over H-shares reached 131.61%, ranking 14th among AH shares in terms of premium rate [1] - Haiprui's A-shares closed at 13.17 yuan, down 0.6%, and H-shares closed at 6.22 Hong Kong dollars, remaining flat [1] Group 2 - Shenzhen Haiprui Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [1] - The company operates across the entire heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [1] - Haiprui's three business segments are synergistic and driven by unmet clinical needs, aiming to provide high-quality, safe, and effective drugs and services to global patients [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 深圳市海普瑞藥業集團股份有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09989 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 220,094,500 | RMB | | 1 RMB | | 220,094,500 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 220,094,500 | RMB | | 1 RMB | | 220,094,500 | | 2. 股份分類 | 普通股 | 股份類別 | A ...

Core Viewpoint - Haiprime, a leading multinational pharmaceutical company, is benefiting from the depreciation of the RMB and its focus on innovative drugs and biopharmaceuticals [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company reported that 93.04% of its revenue comes from overseas, benefiting from the depreciation of the RMB [3]. - As of March 31, 2025, Haiprime's revenue reached 1.394 billion yuan, a year-on-year increase of 1.53%, with a net profit of 157 million yuan, up 1.00% [7]. Financial Performance - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. - The average trading cost of Haiprime's shares is 11.29 yuan, with the current stock price fluctuating between resistance at 13.88 yuan and support at 12.41 yuan [6]. Market Activity - On August 1, Haiprime's stock fell by 1.05%, with a trading volume of 111 million yuan and a turnover rate of 0.66%, bringing the total market capitalization to 19.442 billion yuan [1]. - The main capital flow showed a net outflow of 5.9454 million yuan, indicating a reduction in main capital positions over the past three days [4][5].

Core Viewpoint - The article discusses the performance and business operations of Haiprui, a leading multinational pharmaceutical company, highlighting its revenue structure and market dynamics, particularly in relation to the depreciation of the Chinese yuan and its impact on overseas revenue [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and operates with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company’s main business revenue composition includes: formulations (56.55%), heparin sodium and low molecular weight heparin raw materials (20.25%), CDMO (19.58%), and others (3.63%) [7]. - As of March 31, 2025, Haiprui reported a revenue of 1.394 billion yuan, a year-on-year increase of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up 1.00% year-on-year [7]. Financial Performance - Haiprui's overseas revenue accounts for 93.04% of its total revenue, benefiting from the depreciation of the yuan [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Dynamics - The stock experienced a decline of 1.40% on July 31, with a trading volume of 152 million yuan and a turnover rate of 0.91%, resulting in a total market capitalization of 19.647 billion yuan [1]. - The stock's average trading cost is 11.28 yuan, with recent buying activity observed, although the buying pressure is not strong [6]. - The stock is currently trading between resistance at 13.88 yuan and support at 12.41 yuan, indicating potential for range trading [6]. Institutional Holdings - As of March 31, 2025, Haiprui's top ten circulating shareholders include Hong Kong Central Clearing Limited and Innovation Drug, with increases in their holdings compared to the previous period [8].

本文源自：金融界 作者：行情君 海普瑞AH溢价达122.85%，位居AH股溢价率第17位。当日收盘，海普瑞A股报13.58元，跌幅0.15%，H 股报6.66港元，下跌2.63%。 资料显示，深圳市海普瑞药业集团股份有限公司于1998年成立于深圳,是拥有A+H双融资平台的领先跨 国制药企业,主要业务覆盖肝素全产业链、生物大分子CDMO和创新药物的投资、开发及商业化。公司 的三大板块业务相互协同,以临床未满足需求为驱动,致力于为全球患者提供高质量的安全有效药物和服 务,护佑健康。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 7月30日，上证指数涨0.17%，收报3615.72点，恒生指数跌1.36%，收报25176.93点。 ...

Core Viewpoint - As of July 18, 160 stocks reached their 52-week highs, with notable performances from China New Economy Investment (00080), Aoyuan Group Equity (02905), and Zhong An Holdings Group (08462) showing high growth rates of 288.89%, 55.28%, and 50.00% respectively [1][2]. Summary by Category 52-Week High Performers - China New Economy Investment (00080) closed at 0.440, with a peak price of 0.700, achieving a growth rate of 288.89% [2]. - Aoyuan Group Equity (02905) closed at 0.218, with a peak price of 0.250, achieving a growth rate of 55.28% [2]. - Zhong An Holdings Group (08462) closed at 0.221, with a peak price of 0.228, achieving a growth rate of 50.00% [2]. - Other notable performers include Hualian International (00969) with a growth rate of 40.13% and Zhongke Bio (01237) with a growth rate of 37.25% [2]. Additional High Performers - Wanma Holdings (06928) closed at 0.550 with a growth rate of 30.43% [2]. - Lepu Biopharma-B (02157) closed at 7.940 with a growth rate of 24.54% [2]. - Other stocks with significant growth include ZhiJianYueDong (06860) at 17.14% and China Jindian Group (08281) at 17.12% [2]. 52-Week Low Performers - The document also lists stocks that reached their 52-week lows, with XI Ernan CO-U (09311) showing a decline of 16.10% [6]. - Other notable declines include XI Ernan CO (07311) at -12.62% and Haotian International Construction Investment (01341) at -5.70% [6].

近日，深圳市海普瑞药业集团股份有限公司（以下简称"海普瑞"或"公司"） 自主研发的创新候选药物注射用 H1710（以下简称"H1710"）I 期临床试验已完 成首例受试者入组及首次给药。现将相关情况公告如下： 一、 注射用 H1710 的基本情况 证券代码： 002399 证券简称：海普瑞 公告编号：2025-028 深圳市海普瑞药业集团股份有限公司 关于H1710完成I期临床试验首例受试者入组 及首次给药的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳市海普瑞药业集团股份有限公司 董事会 注射用H1710是一种低抗凝活性的肝素衍生物，是海普瑞自主研发的高效高选 择性的乙酰肝素酶（HPA）抑制剂。乙酰肝素酶在多种恶性肿瘤中高表达，并且与 肿瘤的生长和转移密切相关。H1710通过抑制乙酰肝素酶的活性和表达，展现出抗 肿瘤作用。H1710作为靶向乙酰肝素酶的全新化合物，具有更为合理的链长和独特 的柔性结构，是一种高效、高选择性的乙酰肝素酶抑制剂。 二、 临床试验的相关情况 公司于2025年2月获得国家药品监督管理局核准签发的《药物临床试验批准通 知书》 ...

Core Viewpoint - The company has completed the enrollment and first dosing of the first subject in the Phase I clinical trial for its innovative candidate drug H1710, which is a low anticoagulant activity heparin derivative and a highly selective HPA inhibitor [1] Group 1 - The clinical trial for H1710 is an open-label, dose-escalation Phase I study [1] - The trial aims to evaluate the safety, tolerability, and preliminary anti-tumor activity of H1710 in patients with advanced solid tumors [1] - Approximately 36 patients are expected to be enrolled in the trial [1]

Core Viewpoint - The report outlines the management of the 2024 bond issuance by Shenzhen Hepalink Pharmaceutical Group Co., Ltd, detailing the bond's approval, issuance, financial performance, and compliance with regulations [1][2][5]. Section 1: Bond Overview - The bond, named "22 Hepalink," was approved on March 16, 2022, with a total issuance scale of 500 million yuan, and it was listed on the Shenzhen Stock Exchange on April 11, 2022 [2][3]. - The bond includes options for interest rate selection, issuer redemption, and investor repurchase [2][3]. Section 2: Management of Bond Issuance - The bond trustee, Guotou Securities, is responsible for monitoring the issuer's credit status, fund usage, and repayment of principal and interest [5]. - No bondholder meetings were held during the reporting period [5]. Section 3: Issuer's Business and Financial Status - Shenzhen Hepalink is a leading multinational pharmaceutical company with a registered capital of 1,467.30 million yuan, focusing on the heparin industry chain and CDMO services [6]. - For the first nine months of 2023, the company reported a gross margin of 33.04% and a net profit of 714.69 million yuan [6]. Section 4: Financial Data - As of September 30, 2023, total assets were 201.21 billion yuan, a decrease from the previous year, while total liabilities were 76.22 billion yuan, also down from the previous year [7]. - The net profit for the first nine months of 2023 was 141.89 million yuan, compared to 714.69 million yuan for the entire previous year [7]. - The cash flow from operating activities was negative at -233.99 million yuan, while cash flow from investing activities was positive at 1.31 billion yuan [7]. Section 5: Fund Usage and Disclosure - The bond's proceeds were used to repay the principal of the "19 Hepalink" bond, in line with the bond issuance agreement [8][9]. - The total amount raised after deducting underwriting fees was 496 million yuan [8]. Section 6: Debt Repayment and Guarantees - The bond was fully repaid on April 1, 2024, with no delays in principal or interest payments [10][11]. - The bond is backed by an unconditional and irrevocable guarantee from Shenzhen High-tech Investment and Financing Guarantee Co., Ltd, which has maintained a stable financial condition [10][11]. Section 7: Credit Rating - The issuer's long-term credit rating is AA+, and the bond's credit rating is AAA, with a stable outlook as of May 25, 2023 [12].